# Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral

> **NCT04025567** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Metastatic Hepatocellular Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **DRUG:** vancomycin

## Key facts

- **NCT ID:** NCT04025567
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-03-12
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** slow/insufficient accrual.
- **Last updated:** 2020-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04025567

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04025567, "Vancomycin in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLC) Oral". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04025567. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*